经销商如何避免炒药公司的陷阱（How dealers avoid the trap of fried medicine company）.docVIP

经销商如何避免炒药公司的陷阱（How dealers avoid the trap of fried medicine company） Pharmaceutical enterprises as an important part of the pharmaceutical circulation, has played an important role in the development of the pharmaceutical industry, but also brought business opportunities and profits to many dealers. But as the pharmaceutical industry in the huge profits under the stimulation of explosive development, the problem of product homogeneity, brand spread and vicious competition, resulting in market competition fierce, in the face of such a situation, some pharmaceutical enterprises not to think about how to enhance the core competitiveness, how to improve the service and innovation in marketing, but for money for the purpose of frying, playing a fudge. So the dealer in the choice of partners and products is very careful, a little mistake will fall into the trap of the beautiful fried medicine companies set the money into a living dead stock in warehouse, buy real back off, causing irreparable damage to the dealer. Then, pharmaceutical enterprises generally have those traps, and how should dealers choose the cooperation companies to avoid these traps? The author with many years of experience in the pharmaceutical industry, summed up as follows, hoping to provide a reference for the vast number of dealers: Trap one, the original data fraud Many dealers due to lack of knowledge of general medicine and pharmacological knowledge (especially the new dealers just entering the industry), and as affected by the market, quick success, blindly follow the trend, resulting in product selection, rarely in-depth understanding of products, prescription data and clinical report only to businesses to provide for on the basis of. This has provided an opportunity for some bad pharmaceutical companies. In order to meet the needs of dealers this quick psychology, these fried medicine of the manufacturers to provide prescription data, clinical report, test report and product efficacy of origina